News articles about Achaogen (NASDAQ:AKAO) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Achaogen earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.3999646018764 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8, (nasdaq.com)
- Achaogen, Inc. (AKAO) Given Buy Rating at Mizuho (americanbankingnews.com)
- Can Achaogen Turn It Around After A Long Slide? – Seeking Alpha (seekingalpha.com)
- What Does Technical Indicators say About Achaogen, Inc. (NASDAQ:AKAO)? – The Oracle Examiner (oracleexaminer.com)
- Achaogen (AKAO) Reports FDA Submission of Plazomicin New Drug Application – StreetInsider.com (streetinsider.com)
Achaogen (NASDAQ AKAO) traded down 8.36% during midday trading on Monday, hitting $12.49. 1,187,969 shares of the company’s stock traded hands. The company’s market capitalization is $527.49 million. Achaogen has a 52 week low of $3.68 and a 52 week high of $27.79. The company has a 50 day moving average of $14.88 and a 200-day moving average of $19.76.
Achaogen (NASDAQ:AKAO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.18). Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.69 million. During the same period last year, the firm earned ($0.87) EPS. The company’s revenue was down 85.7% compared to the same quarter last year. Equities research analysts predict that Achaogen will post ($2.99) earnings per share for the current year.
A number of research firms have recently weighed in on AKAO. Mizuho reaffirmed a “buy” rating and set a $28.00 price target on shares of Achaogen in a research note on Monday. Guggenheim assumed coverage on shares of Achaogen in a research note on Tuesday, October 24th. They issued a “buy” rating and a $17.00 price objective on the stock. Leerink Swann reissued an “outperform” rating and issued a $22.00 price objective (down from $28.00) on shares of Achaogen in a research note on Monday, October 9th. They noted that the move was a valuation call. BidaskClub raised shares of Achaogen from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $30.00 price objective on shares of Achaogen in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $26.48.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/10/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-achaogen-akao-stock-price.html.
In other news, COO Blake Wise sold 3,576 shares of Achaogen stock in a transaction dated Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total transaction of $57,180.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 8.36% of the company’s stock.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
What are top analysts saying about Achaogen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Achaogen Inc. and related companies.